AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Recent Alzheimer's disease dynamics are a positive for Biogen's Leqembi - analyst
March 11, 2024 2:01 PM EDTOn Monday, Oppenheimer reiterated its Outperform rating and $290 price target for Biogen (NASDAQ: BIIB) amid recent developments in the Alzheimer's Disease (AD) treatment landscape. The competitive dynamics have shifted significantly, potentially benefiting Biogen's AD drug, Leqembi, which is developed in partnership with Eisai. Eisai has reported progress on multiple fronts for Leqembi, while a competitor, Eli Lilly, announced an unexpected delay for its AD drug,... More
